Alnylam Pharmaceuticals (ALNY) Other financing activities (2018 - 2026)

Alnylam Pharmaceuticals (ALNY) has 8 years of Other financing activities data on file, last reported at -$9000.0 in Q1 2026.

• For the quarter ending Q1 2026, Other financing activities changed N/A year-over-year to -$9000.0; the trailing twelve-month figure through Mar 2026 stood at -$9000.0 (up 99.71% YoY), and the FY2025 full-year result was $2.4 million, changed N/A from the prior year.
• Other financing activities for Q1 2026 stood at -$9000.0, up from -$1.8 million in the prior quarter.
• Across five years, Other financing activities topped out at $8.3 million in Q3 2023 and bottomed at -$16.3 million in Q4 2023.
• The 4-year median for Other financing activities is $4.0 million (2023), against an average of $2.6 million.
• The widest annual swing landed in 2022, when Other financing activities jumped 174.97%; it then slumped 317.77% in 2023.
• A 4-year view of Other financing activities shows it stood at $7.5 million in 2022, then plunged by 317.77% to -$16.3 million in 2023, then soared by 89.16% to -$1.8 million in 2024, then jumped by 99.49% to -$9000.0 in 2026.
• The last three Other financing activities figures came in at -$9000.0 (Q1 2026), -$1.8 million (Q3 2024), and -$1.3 million (Q2 2024), per Business Quant data.

Peer Comparison